155 related articles for article (PubMed ID: 22175142)
41. [New biological therapeutic options for the treatment of RE: inhibition of costimulatory molecules and blockade of Interleukin-6-interaction].
Perniok A; Rubbert-Roth A
Z Rheumatol; 2003 Oct; 62(5):433-8. PubMed ID: 14579030
[TBL] [Abstract][Full Text] [Related]
42. Role of interleukin 1 and interleukin 1 receptor antagonist in the mediation of rheumatoid arthritis.
Schiff MH
Ann Rheum Dis; 2000 Nov; 59 Suppl 1(Suppl 1):i103-8. PubMed ID: 11053099
[TBL] [Abstract][Full Text] [Related]
43. Rheumatoid arthritis therapy after tumor necrosis factor and interleukin-1 blockade.
Redlich K; Schett G; Steiner G; Hayer S; Wagner EF; Smolen JS
Arthritis Rheum; 2003 Dec; 48(12):3308-19. PubMed ID: 14673982
[No Abstract] [Full Text] [Related]
44. [Reactivation of the cryopyrin-associated periodic syndrome after vaccination in a patient who is a candidate for immunosuppression].
Fernández-Prada M; Rugeles-Niño J; Suárez-Pérez L; Ruiz-Álvarez M; López-Díaz JB; Fernández-Madera J; Martínez-Ortega C; Huerta-González I
Rev Esp Quimioter; 2019 Aug; 32(4):379-380. PubMed ID: 31241279
[No Abstract] [Full Text] [Related]
45. Post-inflammatory retinal dystrophy in CINCA syndrome.
Rigante D; Stabile A; Minnella A; Avallone L; Ziccardi L; Bersani G; Stifano G; Compagnone A; Falsini B
Rheumatol Int; 2010 Jan; 30(3):389-93. PubMed ID: 19424698
[TBL] [Abstract][Full Text] [Related]
46. Current management: Management of rheumatic diseases in the era of biological anti-rheumatic drugs.
Konttinen YT; Seitsalo S; Lehto M; Santavirta S
Acta Orthop; 2005 Oct; 76(5):614-9. PubMed ID: 16263606
[No Abstract] [Full Text] [Related]
47. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis.
Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Andreadou I; Nikolaou M; Kaplanoglou T; Katsimbri P; Skarantavos G; Soucacos P; Kremastinos DT
Heart; 2009 Sep; 95(18):1502-7. PubMed ID: 19482847
[TBL] [Abstract][Full Text] [Related]
48. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist.
Bresnihan B
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I96-8. PubMed ID: 10577983
[No Abstract] [Full Text] [Related]
49. Resolution of pericardial constriction with Anakinra in a patient with effusive-constrictive pericarditis secondary to rheumatoid arthritis.
Schatz A; Trankle C; Yassen A; Chipko C; Rajab M; Abouzaki N; Abbate A
Int J Cardiol; 2016 Nov; 223():215-216. PubMed ID: 27541656
[No Abstract] [Full Text] [Related]
50. Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003).
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Dougados M; Emery P; Gibofsky A; Kavanaugh AF; Keystone EC; Klareskog L; Russell AS; van de Putte LB; Weisman MH
Ann Rheum Dis; 2003 Nov; 62 Suppl 2(Suppl 2):ii2-9. PubMed ID: 14532138
[No Abstract] [Full Text] [Related]
51. Monogenic Auto-inflammatory Syndromes: A Review of the Literature.
Azizi G; Khadem Azarian S; Nazeri S; Mosayebian A; Ghiasy S; Sadri G; Mohebi A; Khan Nazer NH; Afraei S; Mirshafiey A
Iran J Allergy Asthma Immunol; 2016 Dec; 15(6):430-444. PubMed ID: 28129677
[TBL] [Abstract][Full Text] [Related]
52. IL-1 inhibition with anakinra in a patient with refractory gout.
Singh D; Huston KK
J Clin Rheumatol; 2009 Oct; 15(7):366. PubMed ID: 20009976
[No Abstract] [Full Text] [Related]
53. CINCA syndrome with surgical intervention for valgus deformity and flexion contracture of the knee joint: A case report.
Harada Y; Fukiage K; Nishikomori R; Suzuki S; Futami T
Mod Rheumatol; 2017 Nov; 27(6):1098-1100. PubMed ID: 25867226
[TBL] [Abstract][Full Text] [Related]
54. Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis.
Timlin H; Bingham CO
Expert Opin Biol Ther; 2014 Jul; 14(7):893-904. PubMed ID: 24720727
[TBL] [Abstract][Full Text] [Related]
55. [Remission--therapy goal in rheumatoid arthritis].
Z Rheumatol; 2007 Feb; 66(1):2 p following 87. PubMed ID: 17896425
[No Abstract] [Full Text] [Related]
56. IL-1 blockade in Schnitzler syndrome: ex vivo findings correlate with clinical remission.
Ryan JG; de Koning HD; Beck LA; Booty MG; Kastner DL; Simon A
J Allergy Clin Immunol; 2008 Jan; 121(1):260-2. PubMed ID: 17936890
[No Abstract] [Full Text] [Related]
57. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
58. [Kineret, Enbrel, Remicade and company. Recombinant drugs in rheumatoid arthritis].
Zündorf I; Dingermann T
Pharm Unserer Zeit; 2003; 32(5):376-83. PubMed ID: 14526457
[No Abstract] [Full Text] [Related]
59. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study.
Hoffman HM; Throne ML; Amar NJ; Cartwright RC; Kivitz AJ; Soo Y; Weinstein SP
Clin Ther; 2012 Oct; 34(10):2091-103. PubMed ID: 23031624
[TBL] [Abstract][Full Text] [Related]
60. Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome.
de Koning HD; Schalkwijk J; van der Meer JW; Simon A
J Allergy Clin Immunol; 2011 Dec; 128(6):1352-4. PubMed ID: 21704363
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
